Table 1.
Characteristics of the patients, and their tumors and treatments
| WORTH 1 (n = 123) | WORTH 2 (n = 198) | Total (n = 321) | |
|---|---|---|---|
| Median age at operation | 65 (range 51–84) | 66 (range 50–84) | 65 (range 50–84) |
| Median tumor size by palpation | 1.6 cm (range 0–3.0 cm) | 1.4 cm (range 0–4.0 cm) | 1.5 cm (range 0–4.0 cm) |
| Personal history of cancer | |||
| Yes | 5 (4.2%) | 19 (9.6%) | 24 (7.5%) |
| No | 118 (95.9%) | 179 (90.4%) | 297 (92.5%) |
| Axillary surgeries | |||
| Sentinel node biopsy | 75 (61.0%) | 183 (92.4%) | 258 (80.4%) |
| Axillary dissection | 44 (35.8%) | 8 (4.0%) | 52 (16.2%) |
| None | 3 (2.4%) | 7 (3.5%) | 10 (3.1%) |
| Unknown | 1 (0.8%) | 0 | 1 (0.3%) |
| Progesterone receptor status | |||
| Positive | 86 (69.9%) | 171 (86.4%) | 257 (80.1%) |
| Negative | 37 (30.1%) | 27 (13.6%) | 64 (19.9%) |
| HER2 status | |||
| Positive | 2 (1.6%) | 1 (0.5%) | 3 (0.9%) |
| Negative (IHC 2 + but FISH was not done) | 105 (85.4%) (5) | 190 (96.0%) (3) | 295 (91.9%) (8) |
| Unknown | 16 (13.0%) | 7 (3.5%) | 23 (7.2%) |
| Histological types | |||
| Invasive ductal cancer | 102 (82.9%) | 174 (87.9%) | 276 (86.0%) |
| Ductal carcinoma in situ | 10 (8.1%) | 11 (5.6%) | 21 (6.5%) |
| Others | 11 (8.9%) | 13 (6.6%) | 24 (7.5%) |
| Adjuvant hormonal agents | |||
| Tamoxifen | 86 (69.9%) | 15 (7.6%) | 101 (31.5%) |
| Aromatase inhibitors | 34 (27.6%) | 178 (89.9%) | 212 (66.0%) |
| Others | 2 (toremifene) (1.6%) | 0 | 2 (0.6%) |
| Unknown | 1 (0.8%) | 4 (2.0%) | 5 (1.6%) |
| None | 0 | 1 (0.5%) | 1 (0.3%) |
| Adjuvant chemotherapy | |||
| Yes | 0 | 3 (1.5%) | 3 (0.9%) |
| No | 122 (99.2%) | 192 (97.0%) | 314 (97.8%) |
| Unknown | 1 (0.8%) | 3 (1.5%) | 4 (1.2%) |